메디톡스

086900KOSDAQ

55.3 / 100

Reference Date: 2026-09-08

Financial Score18.5 / 40

News Sentiment18.8 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE falls significantly short of the industry average. Declined 13.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Medytox specializes in the research, development, manufacturing, and sales of biopharmaceuticals using botulinum toxin type A, with flagship products such as Meditoxin® and Innotox®. In 2024, its key pharmaceutical products accounted for approximately 84% of consolidated revenue, and the company has expanded exports to over 30 countries.

Number of Employees

753people

Average Salary

64.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

29.27Industry Average 15.001.5Point

2.0x industry avg (risky)

PBR

1.11Industry Average 1.204.0Point

In line with industry avg

ROE

3.39Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

4.99Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.8% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲0.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.0% (improving, 3yr)

Detailed News Sentiment

16 totalPositive 13Neutral 2Negative 1Average Sentiment Score 75

Positive
메디톡스, 필러 ‘아띠에르’ 3종 콜롬비아서 허가…“중남미 시장 공.....
메디톡스의 콜롬비아 시장 진출 확대로 필러 포트폴리오 확장 및 시장 확대 기대.
Positive
메디톡스 'K-필러' 3종…콜롬비아서도 팔린다
메디톡스의 콜롬비아 시장 진출로 K-필러의 글로벌 확장이 가속화되어 긍정적인 시장 반응을 기대할 수 있다.
Neutral
아름다움과 건강 모두 잡는다… 뷰티위크로 간 헬스케어 기업들
메디톡스의 제품들이 서울뷰티위크에 소개되었으나, 직접적인 주식 영향은 제한적임.

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 69,400Won52-week high 138,60052-week low 66,900

1-month return1.0Point

1m -13.03% (falling)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-08-28
Neutral반기보고서 (2026.06)2026-08-13
Neutral연결재무제표기준영업(잠정)실적(공정공시)2026-08-10